Sporadic non-A, non-B hepatitis is the most common indication for liver transplantation in patients presenting with fulminant and subacute liver failure. This study used serological, histological, and molecular biological techniques to examine specimens from 23 consecutive patients transplanted for sporadic non-A, non-B hepatitis. No evidence was found of hepatitis C virus, hepatitis E virus, or 'cryptic' hepatitis B virus infection. (Gut 1995; 36: 433-436) 
Liver transplantation is an established treatment for patients presenting with fulminant hepatic failure.' Paracetamol poisoning is the most common cause of fulminant hepatic failure in patients referred to the liver unit at the Queen Elizabeth Hospital, but few of these patients are suitable candidates for liver transplantation.2 Series reported before the application of liver transplantation for fulminant hepatic failure highlighted the particularly poor prognosis of patients who were negative for both hepatitis A (HAV) and hepatitis B (HBV) serological markers.3 4 Sporadic non-A, non-B (NANB) hepatitis is the most common indication for liver transplantation in patients with fulminant hepatic failure referred to our liver unit (two of three of patients transplanted for fulminant and subacute hepatic failure). A review of the published experiencel confirms that fulminant NANB hepatitis or 'hepatitis of unknown aetiology' is the indication for liver transplantation in 50% or more of patients transplanted for fulminant hepatic failure.
The virus responsible for most cases of posttransfusion NANB hepatitis (hepatitis C virus (HCV)) and that responsible for water borne epidemic NANB hepatitis (hepatitis E virus (HEV)) have recently been characterised.5 6 Cases of fulminant sporadic NANB hepatitis can now be examined for markers of HCV and HEV infection. In addition, the application of sensitive techniques such as the polymerase chain reaction to the investigation of these patients may incriminate 'cryptic' HBV infection in the absence of conventional HBV markers. 7 We have examined acute and convalescent specimens from All pretransplant serum samples were negative for both anti-HCV and HCV RNA.
Convalescent serum samples (from 1 1 survivors) collected three to 26 months (median 10) after transplantation were also anti-HCV negative.
Explanted 20 HBV sequences may, however, be detected by polymerase chain reaction in the same setting.21 22 We have used primers from a highly conserved region of the HBV genome in examining 22 explanted livers for evidence of HBV infection. HBV sequences were not detected. Wright et al 7 recently reported 'cryptic' HBV infection (diagnosis based on the detection of HBV sequences in explanted liver by polymerase chain reaction) in patients previously labelled as fulminant NANB hepatitis. Though chronic hepatitis B infection has been shown to occur in the absence of conventional serological markers,23 the absence of a measurable immunological response at the time of fulminant hepatitis B infection seems in contrast with current concepts of host-virus interaction in this setting. It is unlikely that cryptic HBV infection seen in patients described by Wright et al was responsible for the development of fulminant hepatic failure. The appearance of detectable HBsAg in the serum of some of these patients after liver transplantation is probably due to the immunosuppression of patients who had very low concentrations (undetectable by routine testing) of viraemia at presentation. Indeed, the same group of investigators subsequently report the occurrence of 'cryptic' HBV infection in patients transplanted for end stage chronic liver disease.24 The discovery of HBV infection after transplantation (when both donor and recipient were lacking serological markers pretransplantation) may reflect a high prevalence of antecedent HBV exposure in the donor or recipient populations, or both of that transplant programme.
HBV We have previously reported an increased incidence of chronic hepatitis in the post-transplant liver biopsy specimens of patients transplanted for fulminant NANB hepatitis.28 Aggressive chronic hepatitis progressing to cirrhosis has been described in the native liver of a patient undergoing auxiliary liver transplantation for fulminant NANB hepatitis.29
These findings are consistent with a viral aetiology for this syndrome.
Fulminant NANB hepatitis is the most common cause of acute liver failure treated by liver transplantation. Recurrent disease (? reinfection) may occur but is rarely the cause of acute liver failure, a situation similar to that seen in patients transplanted for HCV infection. More than 80 patients with fulminant NANB have been transplanted in Birmingham. A single case of recurrent subacute hepatitis has been seen in this cohort -a 22 year old woman developed liver failure resulting from severe hepatitis that developed in the graft after 18 months of chronic hepatitis. She died shortly after retransplantation and histological changes in the damaged allograft were similar to those seen in the native liver.
The longterm prognosis (with respect to recurrent disease) of patients transplanted for fulminant NANB hepatitis remains uncertain. 
